Price: 86.13

Today's Change: 0.14

Today's Percent Change: 0.39%

Today's Volume: 846361

Average Daily Volume: 1572760

52 week low: 66.93

52 week high: 86.9

Market cap: 201790000000.0

EBITDA: 14460000000.0

EBITDA / market_cap: 7.17%

Earnings per Share (EPS): 2.74

EPS / price: 3.18%

Dividend Yield: 3.16%

Dividend per share: 2.72

Book value: 29.84

Price to Book Ratio: 2.88

Price to Earnings (P/E) Ratio: 31.45

Price to Earnings Growth (PEG) Ratio: 3.23

Price to Sales (P/S) Ratio: 4.1

Short Ratio: 1.69

Exchange: "NYQ"

Short term: UP (Previous: UP)

Mid term: UP (Previous: UP)

Long term: UP (Previous: UP)

Support: 72.70

Resistance: 73.18

Pivot point: 72.95

SMA 10: 73.69

SMA 50: 74.24

SMA 100: 71.49

RSI 10: 33.64

RSI 50: 49.86

RSI 100: 50.15

EMA 10: 73.80

EMA 50: 74.13

EMA 100: 70.67

STRONG BUY

Based on 12 buy signals and 0 sell signals

Previous signal: strong buy

73.91

NEGATIVE

NVS
NVS

@megtirrell: .@jimcramer w $NVS CEO @VasNarasimhan @MelissaLeeCNBC w $UTHR CEO Martine Rothblatt @Skybiome @davidfaber w… https://t.co/zpkr2xfdT3

@shortvolumes: Short sale volume(not short interest) for $BMY on 2019-05-17 is 53%. https://t.co/ZgrXNA0a1Z $AZN 48% $NVS 61% $LLY 39% $JNJ 47%

@DataTrials: $NVS Phase 1|Phase 2 RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome… Estimated Primary Completion Date - 06/2019

@DataTrials: $NVS Phase 1 A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007… https://t.co/iAYAGZkntl

@DataTrials: $NVS Phase 2 Everolimus for Cancer With TSC1 or TSC2 Mutation… Estimated Primary Completion Date - 06/2019

@DataTrials: $NVS Phase 2 Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who… https://t.co/DJcHgiAo26

@DataTrials: $NVS Phase 1|Phase 2 Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma… https://t.co/VmKbFhzol2

@DataTrials: $NVS Phase 3 Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma… Estimated Prim… https://t.co/UkNghO7PRz

@DataTrials: $NVS Phase 2 Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma… Estimat… https://t.co/fEKPhCbLpu

@DataTrials: $NVS Phase 3 Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With A… https://t.co/LZf9FemTK9

@DataTrials: $NVS Phase 1|Phase 2 Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid… https://t.co/O9vstsjWXi

@DataTrials: $NVS Phase 1 A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma… Estimated Primary Completion Date - 06/2019

@DataTrials: $NVS Phase 1 Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Met… https://t.co/9ZlxAL2qPg

@DataTrials: $NVS Phase 3 Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium… Estimated… https://t.co/5g0srZafi6

@DataTrials: $NVS Phase 2 A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lym… https://t.co/HFpaBs4xE0